PMA device
Agili-C
Smith and Nephew, Inc. · Implant, Resorbable, For Articular Osteochondral Repair (QRU, Class III) · First FDA decision Mar 29, 2022, newest Jun 4, 2026Knee osteoarthritisLigament, tendon and cartilage injuries
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
3
Naming "Agili-C"
MAUDE reports
8
Brand "Agili-C", since 2015
PubMed studies
20
Mentioning "Agili-C"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Agili-C
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Agili-CPMA supplement
P210034-S001 · Decided Jun 4, 2026 · 175 days after receipt · Normal 180 Day Track No User Fee
Device type: Implant, resorbable, for articular osteochondral repair (QRU) · Orthopedic Surgery
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Agili-C", any status and sponsor, newest update first.
- Agili-C™ Implant Performance EvaluationPivotal-lookingCompleted
Smith & Nephew, Inc.Public (SNN)
NCT03299959 · 251 participants · Start Sep 25, 2017 · Primary completion Nov 14, 2024
Device: Agili-C implant · For: Cartilage or Osteochondral Defects in the Knee; Up to Moderate Osteoarthritis
Sites: San Diego, California; New Orleans, Louisiana; Salisbury, Maryland · 26 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Agili-C", and for the whole product code for context.
This brand
8 reports: 0 malfunction, 8 injury, 0 death
Whole product code QRU
10 reports: 0 malfunction, 10 injury, 0 death
Newest reports for this brand
- CARTIHEAL AGILI-CInjury
MW6002083 · Received Sep 10, 2026 · Event dated Apr 1, 2026
Device type: Implant, Resorbable, For Articular Osteochondral Repair (QRU)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Inflammation; Pain; Ambulation or Postural Difficulties; Swelling/ Edema
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Agili-C"[tiab]. The summary above synthesizes these.
- Matrices Used for Cartilage Regeneration.
Bulgarelli A, Ruosi L, Conte P, et al. · Clin Sports Med · 2025Review
- Agili-C implant promotes the regenerative capacity of articular cartilage defects in an ex vivo model.
Chubinskaya S, Di Matteo B, Lovato L, et al. · Knee Surg Sports Traumatol Arthrosc · 2019
- Cell-Free Aragonite-Based Scaffold With Bone Marrow Aspirate Concentrate Augmentation for Osteochondral Defects of the Knee.
Gilat R, Weissman AC, Phillips AR, et al. · Video J Sports Med · 2025
- Novel Treatment Options for Knee Cartilage Defects in 2023.
Ghisa C, Zaslav KR · Sports Med Arthrosc Rev · 2024Review
- Combination of Cartiheal and Osteochondral Allograft for the Treatment of Multifocal Cartilage Defects.
Terry HL, Isenberg LYZ, Gomoll AH, et al. · Video J Sports Med · 2026
- Combined Unicompartmental Knee Arthroplasty and Trochlear Porous Calcium Carbonate Scaffold Implantation: Surgical Technique.
Terry HL, Retzky JS, Neijna AG, et al. · Arthrosc Tech · 2025
- Biomaterials for meniscus and cartilage in knee surgery: state of the art.
Kluyskens L, Debieux P, Wong KL, et al. · J ISAKOS · 2022Review
- Surgical Technique for Treating Focal Osteochondral Knee Lesions Using an Aragonite-Based Biphasic Scaffold.
Wang E, Cancio-Bello AM, Koschmeder KT, et al. · Arthrosc Tech · 2026
- Osteogenic differentiation of human bone marrow-derived mesenchymal stem cells is enhanced by an aragonite scaffold.
Matta C, Sz«cs-Somogyi C, Kon E, et al. · Differentiation · 2019Research Support, Non-U.S. Gov't
- Multilayered biomimetic scaffolds for cartilage repair of the talus. A systematic review of the literature.
Kolar M, Drobnič M · Foot Ankle Surg · 2023Systematic Review
- Novel and Alternative Surgical Techniques for Cartilage Disorders of the Knee.
Bi AS, Chen L, Pace JL, et al. · Instr Course Lect · 2026
- Treatment of hallux rigidus by a novel bi-phasic aragonite-based implant: results of a two year multi-centre clinical trial.
Drobnič M, Vannini F, Kon E, et al. · Int Orthop · 2021Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.